传感器类型
荧光生物传感器
检测对象
细胞内氧化还原状态(intracellular redox potential)、还原型谷胱甘肽/氧化型谷胱甘肽比值(GSH/GSSG ratio);样品基质:活细胞胞质(CHO、161-C、161-T细胞,DMEM微流控培养)
检测原理
CY-RL7由ECFP供体、含4个半胱氨酸的RL7连接肽和EYFP受体组成。在还原性胞质中,RL7保持伸展构象,供体与受体距离较大,FRET效率较低;当diamide进入细胞并氧化GSH,或BSO抑制GCL、BCNU抑制GR导致GSH/GSSG还原力下降时,RL7中半胱氨酸形成二硫键,使蛋白折叠为紧凑构象,ECFP与EYFP距离缩短,FRET效率升高。该构象开关将GSH/GSSG氧化还原状态转换为可测荧光比值。系统通过微流控灌注氧化剂/药物,再用三滤光片FRET成像采集FRET、CFP和YFP通道,计算nFRET并归一化为NFRET,从而实时反映胞内氧化还原变化。
检测灵敏度
—
效应效果
CY-RL7在1 mM diamide刺激下FRET信号快速上升,负对照CY-P14无响应,说明信号来自RL7氧化还原连接肽。未处理CHO细胞在diamide去除后约2–3 min恢复初始FRET;BSO预处理24 h后恢复延迟至10–25 min,BCNU预处理2 h后延迟至10–30 min。161-C细胞中,BSO使恢复延至35–42 min,BCNU延至15–18 min;161-T肿瘤细胞恢复更慢,BSO为80–90 min,BCNU 2 h为37–50 min,BCNU 7 h为63–125 min。传感器可连续多次氧化/洗涤循环,作者认为其可用于实时评估肿瘤细胞氧化还原稳态及靶向GSH/GR药物效应。
传感器的构成
- 微流控基底:Ibidi m-Slide VI组织培养处理微流控通道,承载细胞并控制微环境
- 细胞培养层:CHO、161-C、161-T细胞,表达CY-RL7并提供胞内GSH/GSSG体系
- 识别/传感元件:CY-RL7 FRET蛋白,由ECFP、RL7氧化还原连接肽和EYFP组成,感知氧化还原状态
- 氧化还原连接肽:RL7(8×EAAAK序列,含4个Cys),氧化时形成二硫键并改变构象
- 信号标记物:ECFP供体与EYFP受体,通过FRET效率变化输出荧光信号
- 微流控给药模块:DMEM及含diamide、BSO、BCNU的DMEM,经管路灌注实现氧化剂脉冲与洗涤
- 读出系统:倒置荧光显微镜/共聚焦显微镜、三滤光片FRET通道和EMCCD相机,采集FRET/CFP/YFP强度
中文摘要
选择性调节氧化还原状态可能改善癌症治疗,但长期缺乏实时测量细胞内氧化还原电位的方法。本文报道一种基于FRET的新型遗传编码生物传感器CY-RL7,用于在微流控通道中实时监测肿瘤转化细胞对谷胱甘肽扰动的氧化还原响应。微流控网络用于精确控制细胞附近微尺度流动并外源递送药物。作者以二酰胺(diamide)作为硫醇氧化剂,并以BSO和BCNU分别抑制谷胱甘肽合成与谷胱甘肽还原酶,检测还原型谷胱甘肽(GSH)/氧化型谷胱甘肽(GSSG)稳态回路。实验比较了单个活细胞中GSH耗竭与恢复的实时动力学。结果表明,哺乳动物细胞在急性氧化损伤去除后数分钟内可恢复胞内还原环境;该恢复过程可被BSO、BCNU显著延迟,且在肿瘤细胞中较同基因非肿瘤对照细胞更慢。
英文摘要
Despite the potential benefits of selective redox-modulating strategies for cancer therapy, an efficacious methodology for testing therapies remains elusive because of the difficulty in measuring intracellular redox potentials over time. In this report, we have incorporated a new FRET-based biosensor to follow in real time redox-sensitive processes in cells transformed to be tumorigenic and cultured in a microfluidic channel. A microfluidic network was used to control micro-scale flow near the cells and at the same time deliver drugs exogenously. Subsequently, the response of a redox homeostasis circuit was tested, namely reduced glutathione (GSH)/oxidized glutathione(GSSG), to diamide, a thiol oxidant, and two drugs used for cancer therapies: BSO (L-buthionine-[SR]-sulfoximine) and BCNU (carmustine). The main outcome from these experiments is a comparison of the temporal depletion and recovery of GSH in single living cells in real-time. These data demonstrate that mammalian cells are capable of restoring a reduced intracellular redox environment in minutes after an acute oxidative insult is removed. This recovery is significantly delayed by (i) the inhibition of GSH biosynthesis by BSO; (ii) the inactivation of glutathione reductase by BCNU; and (iii) in tumorigenic cells relative to an isogenic non-tumorigenic control cell line.